Navigation Links
New genetic map will speed up plant breeding of the world's most important medicinal crop
Date:1/14/2010

AUDIO: Professor Ian Graham, the Director of the Centre for Novel Agricultural Products at the University of York, UK, talks about the importance of genetic map of the medicinal plant Artemisia...

Click here for more information.

Plant scientists at the University of York have published the first genetic map of the medicinal herb Artemisia annua. The map is being used to accelerate plant breeding of Artemisia and rapidly develop the species into a high-yielding crop. This development is urgently needed to help meet escalating demand for effective malaria treatments.

Though preventable and treatable, malaria is a serious global health problem, estimated to kill almost a million people every year. The most effective drugs for treating malaria are Artemisinin Combination Therapies (ACTs). Increased funding for malaria treatments means demand for ACTs is expected to double from last year's figures, to around 200 million treatments, by 2012. However, meeting this increased demand will be a challenge: artemisinin is extracted from the plant Artemisia annua, but yields are low, making production expensive. In recent years, Artemisia production has been uneconomic and planting areas have declined, raising fears of shortages.

Plant scientists at the Centre for Novel Agricultural Products (CNAP) in the Department of Biology at the University of York are addressing this problem by using molecular technologies to rapidly improve the Artemisia crop. In the latest issue of Science, they publish the first genetic map of this species, plotting the location on the plant's genome of genes, traits and markers associated with high performance. This will enable scientists to recognise young plants as high performers from their genetics. It will also inform the selection of suitable parent plants for breeding experiments.

The map has been validated in glasshouse experiments that found the top-performing plants had elevated frequencies of genetic indicators for high yield. The project is led by Professor Dianna Bowles and Professor Ian Graham. Professor Graham says "The map is already proving to be an essential tool for us. With our new understanding of Artemisia genetics, we can produce improved, non-GM varieties of Artemisia much faster than would otherwise be possible." This speed is essential. "We intend to get high-yielding seed to farmers in the next 2-3 years in order to supply soaring demand for malaria treatments" explains Professor Dianna Bowles. "This is a really tight deadline and we can only do it with the benefit of the new knowledge provided by the map." The work demonstrates how modern genetics is shortening the timescales needed to turn a wild plant species into a domesticated crop.

The scientists at York are creating the new varieties for use by many thousands of small scale growers in the developing world, for whom the Artemisia crop is an important source of income. The project has just received its second grant from the Bill & Melinda Gates Foundation. This grant will support final development of the new varieties and their delivery to Artemisia producers in Africa and Asia.


'/>"/>

Contact: Elspeth Bartlet
eb526@york.ac.uk
44-019-043-28834
University of York
Source:Eurekalert  

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New genetic map will speed up plant breeding of the world's most important medicinal crop
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading provider ... new solution aimed at combatting fraud, waste and abuse ... introduced at the Action on Disaster Relief conference in ... point for UN agencies and foreign assistance organizations throughout ... waste and abuse are a largely unacknowledged problem in ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Driven by consumers, ... are now the fastest growing categories, finds the ... Actives in Personal Care: Multi-regional Market Analysis and ... management consulting firm Kline. "Biotechnology actives ... make them more effective for skin and hair ...
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... Baltimore, Maryland (PRWEB) , ... ... ... firm, PathSensors, Inc., announced today that in a published evaluation of multiple ... (PNNL), a U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection ...
Breaking Biology Technology: